Why the study?
Managing anticoagulant therapy in patients with mechanical prosthetic valves who develop calcific uremic arteriolopathy poses challenging decision-making in the absence of applicable guidelines.
This case report highlights the clinical dilemma of managing anticoagulation in patients with mechanical heart valves who develop warfarin-associated calciphylaxis, for which there are no applicable guidelines.
Should not yet alter anticoagulation in CUA with mechanical valves; leaves open whether LMWH safely replaces warfarin until lesions resolve.
Calciphylaxis, or calcific uremic arteriolopathy (CUA), is a rare vascular calcific disease that is most often associated with renal dysfunction and warfarin, particularly end-stage renal disease (ESRD). This condition causes debilitatingly painful skin lesions, oftentimes plaques, throughout areas of cutaneous and subcutaneous adiposity. The progression of these lesions to black eschar with ulceration is the hallmark of CUA. In this report, we present the case of a Caucasian female with a past medical history of nephrogenic systemic fibrosis (NSF), ESRD, and mechanical aortic and mitral valves, anticoagulated with warfarin, who developed CUA. In the setting of mechanical prosthetic valves, vitamin K antagonists (VKA) and aspirin are the only evidence-based antithrombotic therapies. This case presents challenging decision-making when managing anticoagulant therapy in the absence of applicable guidelines.
No takes yet. Share an insight, caveat, or question.
Smith et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: